MART-1/GP100 and tyrosinase vaccine(NCI)(MART-1/GP100 and tyrosinase vaccine(NCI))

概要

基本信息

药物类型

通用抗原疫苗、治疗性疫苗

别名-

靶点

gp100 x melan-A

作用方式

抑制剂、调节剂

作用机制

gp100抑制剂(黑素细胞蛋白PMEL抑制剂)、melan-A调节剂(T细胞识别黑素瘤抗原调节剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

转移性黑色素瘤

原研机构

National Cancer Institute

在研机构-

非在研机构

National Cancer Institute

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 MART-1/GP100 and tyrosinase vaccine(NCI) 相关的临床试验

NCT00084656

/ Completed临床2期

An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells. Combining the vaccines with Montanide ISA-51 may cause a stronger immune response and kill more tumor cells. Giving monoclonal antibody therapy together with vaccine therapy may be an effective treatment for stage III or stage IV melanoma.
PURPOSE: This phase II trial is studying how well giving monoclonal antibody therapy together with vaccine therapy works in treating patients with resected stage III or stage IV melanoma.

开始日期2004-05-31

申办/合作机构

Bristol Myers Squibb Co.

[+1]

NCT00334776

/ Completed临床2期IIT

A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells.
PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.

开始日期2003-10-01

申办/合作机构

University of Southern California

[+1]

NCT00001685

/ Completed临床2期IIT

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

This is a study of a melanoma tumor antigen peptide vaccine. Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be administered emulsified in Incomplete Freund's Adjuvant, (IFA) to HLA-A201 patients with melanoma. The study is designed to evaluate the potential therapeutic role, immunologic effects and toxicity of repeated doses of this peptide vaccine administered subcutaneously.
Immune reactivity to the peptide epitope will be monitored in all patients by analysis of melanoma-specific T cell precursors prior to and after immunization.

开始日期1997-11-01

申办/合作机构

National Cancer Institute

100 项与 MART-1/GP100 and tyrosinase vaccine(NCI) 相关的临床结果

登录后查看更多信息

100 项与 MART-1/GP100 and tyrosinase vaccine(NCI) 相关的转化医学

登录后查看更多信息

100 项与 MART-1/GP100 and tyrosinase vaccine(NCI) 相关的专利（医药）

登录后查看更多信息

100 项与 MART-1/GP100 and tyrosinase vaccine(NCI) 相关的药物交易

登录后查看更多信息